Effect of genetic knockout or pharmacologic inhibition of neuronal nitric oxide synthase on complete Freund's adjuvant-induced persistent pain
- 1 December 2005
- journal article
- Published by Wolters Kluwer Health in PAIN®
- Vol. 119 (1-3) , 113-123
- https://doi.org/10.1016/j.pain.2005.09.024
Abstract
Nitric oxide (NO) acts as a neurotransmitter or neuromodulator involving in the modulation of thermal and/or inflammatory hyperalgesia. The neuronal nitric oxide synthase (nNOS) is a key enzyme for NO production in normal neuronal tissues, but its functional role in chronic pain remains unclear. The present study combined a genetic strategy with a pharmacologic approach to address the role of nNOS in the central mechanism of complete Freund's adjuvant (CFA)-induced chronic inflammatory pain. Targeted disruption of the nNOS gene significantly reduced CFA-induced mechanical pain hypersensitivity during the maintenance (but not the development) of inflammatory pain, while it failed to attenuate either development or maintenance of CFA-induced thermal pain hypersensitivity. Intraperitoneal administration of L-N(G)-nitro-arginine methyl ester (L-NAME), a non-specific NOS inhibitor, blocked CFA-evoked thermal and mechanical pain hypersensitivity at both development (2h) and maintenance (24h) phase in wild type mice, but had no effect in the knockout mice. Furthermore, intrathecal injection of either L-NAME or 7-nitroindazole, a selective nNOS inhibitor, markedly attenuated mechanical pain hypersensitivity at both 2 and 24h after CFA injection. Finally, spinal cord nNOS (but not endothelial NOS or inducible NOS) expression was up-regulated at 24h after CFA injection, occurring mainly in the ipsilateral superficial dorsal horn. Together, these data indicate that spinal cord nNOS may be essential for the maintenance of mechanical pain hypersensitivity and that it may also be sufficient for the development of mechanical pain hypersensitivity and for the development and maintenance of thermal pain hypersensitivity after chronic inflammation. Our findings suggest that spinal cord nNOS might play a critical role in central mechanisms of the development and/or maintenance of chronic inflammatory pain.Keywords
This publication has 53 references indexed in Scilit:
- Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2Proceedings of the National Academy of Sciences, 2003
- The involvement of nitric oxide in the analgesic effects of ketamineLife Sciences, 2002
- Suppressed Injury-Induced Rise in Spinal Prostaglandin E2 Production and Reduced Early Thermal Hyperalgesia in iNOS-Deficient MiceJournal of Neuroscience, 2000
- Intrathecal administration of an NMDA or a non-NMDA receptor antagonist reduces mechanical but not thermal allodynia in a rodent model of chronic central pain after spinal cord injuryBrain Research, 2000
- Inhibition of inducible nitric oxide synthase in persistent painLife Sciences, 1999
- Distribution of Protein Inhibitor of Neuronal Nitric Oxide Synthase in Rat BrainBiochemical and Biophysical Research Communications, 1997
- Possible involvement of nitric oxide in NMDA-induced glutamate release in the rat striatum: an in vivo microdialysis studyNeuroscience Letters, 1997
- Intact nociception-induced neuroplasticity in transgenic mice deficient in neuronal nitric oxide synthaseNeuroscience, 1995
- Endothelial nitric oxide synthase localized to hippocampal pyramidal cells: implications for synaptic plasticity.Proceedings of the National Academy of Sciences, 1994
- Nitric oxide synthase immunoreactivity in the rat, mouse, cat and squirrel monkey spinal cordNeuroscience, 1993